AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUVL
  4. [SCHEDULE 13G] Nuvalent, Inc. SEC Filing

[SCHEDULE 13G] Nuvalent, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source:

Stock NUVL logo
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

#1268 Ranked by Market Cap
N/A Ranked by Dividends

NUVL Latest News

Sep 7, 2025
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Aug 28, 2025
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Aug 13, 2025
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
Aug 7, 2025
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results
Jul 21, 2025
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

NUVL Latest SEC Filings

Sep 3, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Aug 27, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Aug 19, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Aug 8, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity
Aug 7, 2025
[10-Q] Nuvalent, Inc. Quarterly Earnings Report

NUVL Stock Data

5.83B
63.39M
2.83%
109.07%
7.44%
Biotechnology
Pharmaceutical Preparations
United States
CAMBRIDGE